<p>RNS 编号：0510E 和黄医药（中国）有限公司 2025 年 10 月 21 日</p>
<p><strong>长期激励计划下奖励的归属</strong></p>
<p>香港、上海及新泽西州弗洛姆公园 -2025 年 10 月 21 日：和黄医药（中国）有限公司（&#34;和黄医药&#34;）（纳斯达克/AIM：HCM；香港交易所：13）宣布，2021 年 10 月 20 日根据长期激励计划（&#34;LTIP&#34;）授予的非业绩基础奖励于 2025 年 10 月 20 日归属给以下管理责任人：-</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>奖励持有人</td>
<td>美国存托股份（&#34;ADS&#34;）数量</td>
</tr>
<tr>
<td>Dr Dan Eldar（非执行董事（&#34;NED&#34;））</td>
<td>1,938</td>
</tr>
<tr>
<td>Ms Edith Shih（NED）</td>
<td>1,938 (1)</td>
</tr>
<tr>
<td>Professor Tony Mok（独立非执行董事）</td>
<td>1,938</td>
</tr>
</tbody>
</table>
<p>注意：</p>
<p>(1) 这些 ADS 并未由 Ms Edith Shih 接收，而是由她的雇主 Hutchison International Limited 接收或为其账户接收。</p>
<p>以下通知是根据英国市场滥用法规的要求提供的。</p>
<p>(a) Dr Dan Eldar</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>负责管理职责的人员/密切相关人员的详细信息</td>
<td></td>
</tr>
<tr>
<td>a)</td>
<td>姓名</td>
<td>Dr Dan Eldar</td>
</tr>
<tr>
<td>2</td>
<td>通知原因</td>
<td></td>
</tr>
<tr>
<td>a)</td>
<td>职位/状态</td>
<td>非执行董事</td>
</tr>
<tr>
<td>b)</td>
<td>初始通知/修订</td>
<td>初始通知</td>
</tr>
<tr>
<td>3</td>
<td>发行人、排放配额市场参与者、拍卖平台、拍卖师或拍卖监控者的详细信息</td>
<td></td>
</tr>
<tr>
<td>a)</td>
<td>名称</td>
<td>和黄医药（中国）有限公司</td>
</tr>
<tr>
<td>b)</td>
<td>LEI</td>
<td>2138006X34YDQ6OBYE79</td>
</tr>
<tr>
<td>4</td>
<td>交易的详细信息：该部分应针对（i）每种类型的工具；（ii）每种类型的交易；（iii）每个日期；以及（iv）每个交易地点重复</td>
<td></td>
</tr>
<tr>
<td>a)</td>
<td>金融工具的描述，工具类型<br/>识别代码</td>
<td>每个 ADS 代表五股面值为 0.10 美元的普通股<br/>ADS ISIN：US44842L1035</td>
</tr>
<tr>
<td>b)</td>
<td>交易性质</td>
<td>根据和黄医药的 LTIP 于 2021 年 10 月 20 日授予的奖励归属</td>
</tr>
<tr>
<td>c)</td>
<td>价格和数量</td>
<td></td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td></td>
</tr>
<tr>
<td>价格</td>
<td>数量</td>
<td></td>
</tr>
<tr>
<td>无</td>
<td>1,938 ADS</td>
<td></td>
</tr>
<tr>
<td>d)</td>
<td>汇总信息</td>
<td>不适用</td>
</tr>
<tr>
<td>e)</td>
<td>交易日期</td>
<td>2025-10-20</td>
</tr>
<tr>
<td>f)</td>
<td>交易地点</td>
<td>在交易场所外</td>
</tr>
</tbody>
</table>
<p>(b) Professor Tony Mok</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>负责管理职责的人员/密切相关人员的详细信息</td>
<td></td>
</tr>
<tr>
<td>a)</td>
<td>姓名</td>
<td>Professor Tony Mok</td>
</tr>
<tr>
<td>2</td>
<td>通知原因</td>
<td></td>
</tr>
<tr>
<td>a)</td>
<td>职位/状态</td>
<td>独立非执行董事</td>
</tr>
<tr>
<td>b)</td>
<td>初始通知/修订</td>
<td>初始通知</td>
</tr>
<tr>
<td>3</td>
<td>发行人、排放配额市场参与者、拍卖平台、拍卖师或拍卖监控者的详细信息</td>
<td></td>
</tr>
<tr>
<td>a)</td>
<td>名称</td>
<td>和黄医药（中国）有限公司</td>
</tr>
<tr>
<td>b)</td>
<td>LEI</td>
<td>2138006X34YDQ6OBYE79</td>
</tr>
<tr>
<td>4</td>
<td>交易的详细信息：该部分应针对（i）每种类型的工具；（ii）每种类型的交易；（iii）每个日期；以及（iv）每个交易地点重复</td>
<td></td>
</tr>
<tr>
<td>a)</td>
<td>金融工具的描述，工具类型<br/>识别代码</td>
<td>每个 ADS 代表五股面值为 0.10 美元的普通股<br/>ADS ISIN：US44842L1035</td>
</tr>
<tr>
<td>b)</td>
<td>交易性质</td>
<td>根据和黄医药的 LTIP 于 2021 年 10 月 20 日授予的奖励归属</td>
</tr>
<tr>
<td>c)</td>
<td>价格和数量</td>
<td></td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td></td>
</tr>
<tr>
<td>价格</td>
<td>数量</td>
<td></td>
</tr>
<tr>
<td>无</td>
<td>1,938 ADS</td>
<td></td>
</tr>
<tr>
<td>d)</td>
<td>汇总信息</td>
<td>不适用</td>
</tr>
<tr>
<td>e)</td>
<td>交易日期</td>
<td>2025-10-20</td>
</tr>
<tr>
<td>f)</td>
<td>交易地点</td>
<td>在交易场所外</td>
</tr>
</tbody>
</table>
<p><strong>关于和黄医药</strong></p>
<p>和黄医药（纳斯达克/AIM：HCM；香港交易所：13）是一家创新的商业阶段生物制药公司。致力于癌症和免疫疾病的靶向疗法和免疫疗法的发现、全球开发和商业化。自成立以来，专注于将药物候选者从内部发现带给全球患者，其首三种药物在中国上市，其中第一种药物也在全球范围内获得批准，包括美国、欧洲和日本。如需更多信息，请访问：www.hutch‑med.com 或关注我们的 LinkedIn。</p>
<p><strong>联系方式</strong></p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>投资者咨询</td>
<td>+852 2121 8200 / ir@hutch-med.com</td>
</tr>
<tr>
<td>媒体咨询</td>
<td></td>
</tr>
<tr>
<td>FTI Consulting -</td>
<td>+44 20 3727 1030 / HUTCHMED@fticonsulting.com</td>
</tr>
<tr>
<td>Ben Atwell / Alex Shaw</td>
<td>+44 7771 913 902 (手机) / +44 7779 545 055 (手机)</td>
</tr>
<tr>
<td>Brunswick - Zhou Yi</td>
<td>+852 9783 6894 (手机) / HUTCHMED@brunswickgroup.com</td>
</tr>
<tr>
<td>Panmure Liberum</td>
<td>指定顾问和联合经纪人</td>
</tr>
<tr>
<td>Atholl Tweedie / Emma Earl / Rupert Dearden</td>
<td>+44 20 7886 2500</td>
</tr>
<tr>
<td>Cavendish</td>
<td>联合经纪人</td>
</tr>
<tr>
<td>Geoff Nash / Nigel Birks</td>
<td>+44 20 7220 0500</td>
</tr>
<tr>
<td>Deutsche Numis</td>
<td>联合经纪人</td>
</tr>
<tr>
<td>Freddie Barnfield / Jeffrey Wong / Duncan Monteith</td>
<td>+44 20 7260 1000</td>
</tr>
</tbody>
</table>
<p>此信息由 RNS 提供，RNS 是伦敦证券交易所的新闻服务。RNS 获得金融行为监管局的批准，作为英国的主要信息提供者。有关使用和分发此信息的条款和条件可能适用。如需更多信息，请联系 rns@lseg.com 或访问 www.rns.com。</p>
<p>RNS 可能会使用您的 IP 地址以确认遵守条款和条件，分析您与本通信中包含的信息的互动方式，并将此分析以匿名方式与他人共享，作为我们商业服务的一部分。如需有关 RNS 和伦敦证券交易所如何使用您提供的个人数据的更多信息，请参阅我们的隐私政策。结束 DSHDZMZGGGRGKZM</p>

和黄医药

<p>和黄医药（中国）有限公司于 2025 年 10 月 20 日宣布根据其长期激励计划（LTIP）授予的非业绩基础奖励的归属。这些奖励于 2021 年 10 月 20 日授予，归属给了 Dan Eldar 博士、Edith Shih 女士和 Tony Mok 教授，每人获得 1,938 份美国存托股票（ADS）。该交易在交易场所外进行，ADS 代表五股面值为 0.10 美元的普通股。和黄医药是一家专注于癌症和免疫疾病治疗的生物制药公司</p>

<p>RNS Number : 0510E Hutchmed (China) Limited 21 October 2025</p>
<div class="lb-trans"><p>RNS 编号：0510E 和黄医药（中国）有限公司 2025 年 10 月 21 日</p>
</div><p><strong>Vesting of awards under the Long Term Incentive Plan</strong></p>
<div class="lb-trans"><p><strong>长期激励计划下奖励的归属</strong></p>
</div><p>Hong Kong, Shanghai &amp; Florham Park, NJ - Tuesday, October 21, 2025: HUTCHMED (China) Limited (&#34;HUTCHMED&#34;) (Nasdaq/AIM: HCM; SEHK:13) announces that the non-performance based awards granted under the Long Term Incentive Plan (&#34;LTIP&#34;) on October 20, 2021 to the following persons discharging managerial responsibilities were vested on October 20, 2025:-</p>
<div class="lb-trans"><p>香港、上海及新泽西州弗洛姆公园 -2025 年 10 月 21 日：和黄医药（中国）有限公司（&#34;和黄医药&#34;）（纳斯达克/AIM：HCM；香港交易所：13）宣布，2021 年 10 月 20 日根据长期激励计划（&#34;LTIP&#34;）授予的非业绩基础奖励于 2025 年 10 月 20 日归属给以下管理责任人：-</p>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Award Holder</td>
<td>Number of American depositary shares (&#34;ADS&#34;)</td>
</tr>
<tr>
<td>Dr Dan Eldar (Non-executive Director (&#34;NED&#34;))</td>
<td>1,938</td>
</tr>
<tr>
<td>Ms Edith Shih (NED)</td>
<td>1,938 (1)</td>
</tr>
<tr>
<td>Professor Tony Mok (Independent Non-executive Director)</td>
<td>1,938</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>奖励持有人</td>
<td>美国存托股份（&#34;ADS&#34;）数量</td>
</tr>
<tr>
<td>Dr Dan Eldar（非执行董事（&#34;NED&#34;））</td>
<td>1,938</td>
</tr>
<tr>
<td>Ms Edith Shih（NED）</td>
<td>1,938 (1)</td>
</tr>
<tr>
<td>Professor Tony Mok（独立非执行董事）</td>
<td>1,938</td>
</tr>
</tbody>
</table>
</div><p>Note:</p>
<div class="lb-trans"><p>注意：</p>
</div><p>(1) These ADSs were not received by Ms Edith Shih, but were received by or for the account of her employer, Hutchison International Limited.</p>
<div class="lb-trans"><p>(1) 这些 ADS 并未由 Ms Edith Shih 接收，而是由她的雇主 Hutchison International Limited 接收或为其账户接收。</p>
</div><p>The notifications set out below are provided in accordance with the requirements of the UK Market Abuse Regulation.</p>
<div class="lb-trans"><p>以下通知是根据英国市场滥用法规的要求提供的。</p>
</div><p>(a) Dr Dan Eldar</p>
<div class="lb-trans"><p>(a) Dr Dan Eldar</p>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Details of the person discharging managerial responsibilities/person closely associated</td>
<td></td>
</tr>
<tr>
<td>a)</td>
<td>Name</td>
<td>Dr Dan Eldar</td>
</tr>
<tr>
<td>2</td>
<td>Reason for the notification</td>
<td></td>
</tr>
<tr>
<td>a)</td>
<td>Position/status</td>
<td>Non-Executive Director</td>
</tr>
<tr>
<td>b)</td>
<td>Initial notification/Amendment</td>
<td>Initial notification</td>
</tr>
<tr>
<td>3</td>
<td>Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</td>
<td></td>
</tr>
<tr>
<td>a)</td>
<td>Name</td>
<td>HUTCHMED (China) Limited</td>
</tr>
<tr>
<td>b)</td>
<td>LEI</td>
<td>2138006X34YDQ6OBYE79</td>
</tr>
<tr>
<td>4</td>
<td>Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</td>
<td></td>
</tr>
<tr>
<td>a)</td>
<td>Description of the financial instrument, type of instrument<br/>Identification code</td>
<td>ADS each representing five Ordinary Shares of US$0.10<br/>ADS ISIN: US44842L1035</td>
</tr>
<tr>
<td>b)</td>
<td>Nature of the transaction</td>
<td>Vesting of awards granted on October 20, 2021 under HUTCHMED's LTIP</td>
</tr>
<tr>
<td>c)</td>
<td>Price(s) and volume(s)</td>
<td></td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td></td>
</tr>
<tr>
<td>Price(s)</td>
<td>Volume(s)</td>
<td></td>
</tr>
<tr>
<td>Nil</td>
<td>1,938 ADS</td>
<td></td>
</tr>
<tr>
<td>d)</td>
<td>Aggregated information</td>
<td>N/A</td>
</tr>
<tr>
<td>e)</td>
<td>Date of the transaction</td>
<td>2025-10-20</td>
</tr>
<tr>
<td>f)</td>
<td>Place of the transaction</td>
<td>Outside a trading venue</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>负责管理职责的人员/密切相关人员的详细信息</td>
<td></td>
</tr>
<tr>
<td>a)</td>
<td>姓名</td>
<td>Dr Dan Eldar</td>
</tr>
<tr>
<td>2</td>
<td>通知原因</td>
<td></td>
</tr>
<tr>
<td>a)</td>
<td>职位/状态</td>
<td>非执行董事</td>
</tr>
<tr>
<td>b)</td>
<td>初始通知/修订</td>
<td>初始通知</td>
</tr>
<tr>
<td>3</td>
<td>发行人、排放配额市场参与者、拍卖平台、拍卖师或拍卖监控者的详细信息</td>
<td></td>
</tr>
<tr>
<td>a)</td>
<td>名称</td>
<td>和黄医药（中国）有限公司</td>
</tr>
<tr>
<td>b)</td>
<td>LEI</td>
<td>2138006X34YDQ6OBYE79</td>
</tr>
<tr>
<td>4</td>
<td>交易的详细信息：该部分应针对（i）每种类型的工具；（ii）每种类型的交易；（iii）每个日期；以及（iv）每个交易地点重复</td>
<td></td>
</tr>
<tr>
<td>a)</td>
<td>金融工具的描述，工具类型<br/>识别代码</td>
<td>每个 ADS 代表五股面值为 0.10 美元的普通股<br/>ADS ISIN：US44842L1035</td>
</tr>
<tr>
<td>b)</td>
<td>交易性质</td>
<td>根据和黄医药的 LTIP 于 2021 年 10 月 20 日授予的奖励归属</td>
</tr>
<tr>
<td>c)</td>
<td>价格和数量</td>
<td></td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td></td>
</tr>
<tr>
<td>价格</td>
<td>数量</td>
<td></td>
</tr>
<tr>
<td>无</td>
<td>1,938 ADS</td>
<td></td>
</tr>
<tr>
<td>d)</td>
<td>汇总信息</td>
<td>不适用</td>
</tr>
<tr>
<td>e)</td>
<td>交易日期</td>
<td>2025-10-20</td>
</tr>
<tr>
<td>f)</td>
<td>交易地点</td>
<td>在交易场所外</td>
</tr>
</tbody>
</table>
</div><p>(b) Professor Tony Mok</p>
<div class="lb-trans"><p>(b) Professor Tony Mok</p>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Details of the person discharging managerial responsibilities/person closely associated</td>
<td></td>
</tr>
<tr>
<td>a)</td>
<td>Name</td>
<td>Professor Tony Mok</td>
</tr>
<tr>
<td>2</td>
<td>Reason for the notification</td>
<td></td>
</tr>
<tr>
<td>a)</td>
<td>Position/status</td>
<td>Independent Non-Executive Director</td>
</tr>
<tr>
<td>b)</td>
<td>Initial notification/Amendment</td>
<td>Initial notification</td>
</tr>
<tr>
<td>3</td>
<td>Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</td>
<td></td>
</tr>
<tr>
<td>a)</td>
<td>Name</td>
<td>HUTCHMED (China) Limited</td>
</tr>
<tr>
<td>b)</td>
<td>LEI</td>
<td>2138006X34YDQ6OBYE79</td>
</tr>
<tr>
<td>4</td>
<td>Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</td>
<td></td>
</tr>
<tr>
<td>a)</td>
<td>Description of the financial instrument, type of instrument<br/>Identification code</td>
<td>ADS each representing five Ordinary Shares of US$0.10<br/>ADS ISIN: US44842L1035</td>
</tr>
<tr>
<td>b)</td>
<td>Nature of the transaction</td>
<td>Vesting of awards granted on October 20, 2021 under HUTCHMED's LTIP</td>
</tr>
<tr>
<td>c)</td>
<td>Price(s) and volume(s)</td>
<td></td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td></td>
</tr>
<tr>
<td>Price(s)</td>
<td>Volume(s)</td>
<td></td>
</tr>
<tr>
<td>Nil</td>
<td>1,938 ADS</td>
<td></td>
</tr>
<tr>
<td>d)</td>
<td>Aggregated information</td>
<td>N/A</td>
</tr>
<tr>
<td>e)</td>
<td>Date of the transaction</td>
<td>2025-10-20</td>
</tr>
<tr>
<td>f)</td>
<td>Place of the transaction</td>
<td>Outside a trading venue</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>负责管理职责的人员/密切相关人员的详细信息</td>
<td></td>
</tr>
<tr>
<td>a)</td>
<td>姓名</td>
<td>Professor Tony Mok</td>
</tr>
<tr>
<td>2</td>
<td>通知原因</td>
<td></td>
</tr>
<tr>
<td>a)</td>
<td>职位/状态</td>
<td>独立非执行董事</td>
</tr>
<tr>
<td>b)</td>
<td>初始通知/修订</td>
<td>初始通知</td>
</tr>
<tr>
<td>3</td>
<td>发行人、排放配额市场参与者、拍卖平台、拍卖师或拍卖监控者的详细信息</td>
<td></td>
</tr>
<tr>
<td>a)</td>
<td>名称</td>
<td>和黄医药（中国）有限公司</td>
</tr>
<tr>
<td>b)</td>
<td>LEI</td>
<td>2138006X34YDQ6OBYE79</td>
</tr>
<tr>
<td>4</td>
<td>交易的详细信息：该部分应针对（i）每种类型的工具；（ii）每种类型的交易；（iii）每个日期；以及（iv）每个交易地点重复</td>
<td></td>
</tr>
<tr>
<td>a)</td>
<td>金融工具的描述，工具类型<br/>识别代码</td>
<td>每个 ADS 代表五股面值为 0.10 美元的普通股<br/>ADS ISIN：US44842L1035</td>
</tr>
<tr>
<td>b)</td>
<td>交易性质</td>
<td>根据和黄医药的 LTIP 于 2021 年 10 月 20 日授予的奖励归属</td>
</tr>
<tr>
<td>c)</td>
<td>价格和数量</td>
<td></td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td></td>
</tr>
<tr>
<td>价格</td>
<td>数量</td>
<td></td>
</tr>
<tr>
<td>无</td>
<td>1,938 ADS</td>
<td></td>
</tr>
<tr>
<td>d)</td>
<td>汇总信息</td>
<td>不适用</td>
</tr>
<tr>
<td>e)</td>
<td>交易日期</td>
<td>2025-10-20</td>
</tr>
<tr>
<td>f)</td>
<td>交易地点</td>
<td>在交易场所外</td>
</tr>
</tbody>
</table>
</div><p><strong>About HUTCHMED</strong></p>
<div class="lb-trans"><p><strong>关于和黄医药</strong></p>
</div><p>HUTCHMED (Nasdaq/AIM:​HCM; HKEX:​13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception it has focused on bringing drug candidates from in-house discovery to patients around the world, with its first three medicines marketed in China, the first of which is also approved around the world including in the US, Europe and Japan. For more information, please visit: www.hutch‑med.com or follow us on LinkedIn.</p>
<div class="lb-trans"><p>和黄医药（纳斯达克/AIM：HCM；香港交易所：13）是一家创新的商业阶段生物制药公司。致力于癌症和免疫疾病的靶向疗法和免疫疗法的发现、全球开发和商业化。自成立以来，专注于将药物候选者从内部发现带给全球患者，其首三种药物在中国上市，其中第一种药物也在全球范围内获得批准，包括美国、欧洲和日本。如需更多信息，请访问：www.hutch‑med.com 或关注我们的 LinkedIn。</p>
</div><p><strong>CONTACTS</strong></p>
<div class="lb-trans"><p><strong>联系方式</strong></p>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Investor Enquiries</td>
<td>+852 2121 8200 / ir@hutch-med.com</td>
</tr>
<tr>
<td>Media Enquiries</td>
<td></td>
</tr>
<tr>
<td>FTI Consulting -</td>
<td>+44 20 3727 1030 / HUTCHMED@fticonsulting.com</td>
</tr>
<tr>
<td>Ben Atwell / Alex Shaw</td>
<td>+44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile)</td>
</tr>
<tr>
<td>Brunswick - Zhou Yi</td>
<td>+852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com</td>
</tr>
<tr>
<td>Panmure Liberum</td>
<td>Nominated Advisor and Joint Broker</td>
</tr>
<tr>
<td>Atholl Tweedie / Emma Earl / Rupert Dearden</td>
<td>+44 20 7886 2500</td>
</tr>
<tr>
<td>Cavendish</td>
<td>Joint Broker</td>
</tr>
<tr>
<td>Geoff Nash / Nigel Birks</td>
<td>+44 20 7220 0500</td>
</tr>
<tr>
<td>Deutsche Numis</td>
<td>Joint Broker</td>
</tr>
<tr>
<td>Freddie Barnfield / Jeffrey Wong / Duncan Monteith</td>
<td>+44 20 7260 1000</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>投资者咨询</td>
<td>+852 2121 8200 / ir@hutch-med.com</td>
</tr>
<tr>
<td>媒体咨询</td>
<td></td>
</tr>
<tr>
<td>FTI Consulting -</td>
<td>+44 20 3727 1030 / HUTCHMED@fticonsulting.com</td>
</tr>
<tr>
<td>Ben Atwell / Alex Shaw</td>
<td>+44 7771 913 902 (手机) / +44 7779 545 055 (手机)</td>
</tr>
<tr>
<td>Brunswick - Zhou Yi</td>
<td>+852 9783 6894 (手机) / HUTCHMED@brunswickgroup.com</td>
</tr>
<tr>
<td>Panmure Liberum</td>
<td>指定顾问和联合经纪人</td>
</tr>
<tr>
<td>Atholl Tweedie / Emma Earl / Rupert Dearden</td>
<td>+44 20 7886 2500</td>
</tr>
<tr>
<td>Cavendish</td>
<td>联合经纪人</td>
</tr>
<tr>
<td>Geoff Nash / Nigel Birks</td>
<td>+44 20 7220 0500</td>
</tr>
<tr>
<td>Deutsche Numis</td>
<td>联合经纪人</td>
</tr>
<tr>
<td>Freddie Barnfield / Jeffrey Wong / Duncan Monteith</td>
<td>+44 20 7260 1000</td>
</tr>
</tbody>
</table>
</div><p>This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.</p>
<div class="lb-trans"><p>此信息由 RNS 提供，RNS 是伦敦证券交易所的新闻服务。RNS 获得金融行为监管局的批准，作为英国的主要信息提供者。有关使用和分发此信息的条款和条件可能适用。如需更多信息，请联系 rns@lseg.com 或访问 www.rns.com。</p>
</div><p>RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. END DSHDZMZGGGRGKZM</p>
<div class="lb-trans"><p>RNS 可能会使用您的 IP 地址以确认遵守条款和条件，分析您与本通信中包含的信息的互动方式，并将此分析以匿名方式与他人共享，作为我们商业服务的一部分。如需有关 RNS 和伦敦证券交易所如何使用您提供的个人数据的更多信息，请参阅我们的隐私政策。结束 DSHDZMZGGGRGKZM</p>
</div>

和黄医药有限公司 - 长期激励计划中的奖励归属